PROS1 and neoplasm: The primary outcome was a ≥ 50% PSA decline, with objective response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, changes in Eastern Cooperative Oncology Group (ECOG) performance status (PS), and circulating tumor cell (CTC) number.